SCHEMBL9114889

SCHEMBL9114889

Cc1cc(Oc2ccccc2)ccc1C=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 2/20 0.50
GAA P10253 2/20 0.50
KMT2A Q03164 2/20 0.50
ALDH1A1 P00352 5/20 0.48
TSHR P16473 2/20 0.48
ERN1 O75460 1/20 0.48
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
CYP1A2 P05177 1/20 0.45
CYP2C9 P11712 1/20 0.45
CYP2C19 P33261 1/20 0.45
NPC1 O15118 1/20 0.44
PKM P14618 1/20 0.44
RAB9A P51151 1/20 0.44
LTA4H P09960 2/20 0.44
MAOA P21397 1/20 0.44
NPSR1 Q6W5P4 1/20 0.44
SMN1; SMN2 Q16637 2/20 0.42
HTT P42858 1/20 0.42
ACHE P22303 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18957581 0.84 MAOA (0.46) ALDH1A1TSHRERN1TDP1MAOA
SCHEMBL18957604 0.84 CYP1A2 (0.42) LMNAGAAKMT2AALDH1A1TSHR
SCHEMBL1849155 0.80 LMNA (0.67) LMNAGAAKMT2AALDH1A1TSHR
SCHEMBL28451899 0.79 ALDH1A1 (0.69) LMNAGAAKMT2AALDH1A1TSHR
SCHEMBL2558631 0.79 PARP10 (0.59) LMNAKMT2AALDH1A1ERN1L3MBTL1
SCHEMBL6467176 0.79 ALDH1A1 (0.47) LMNAALDH1A1TSHRERN1TDP1
SCHEMBL23709919 0.79 LMNA (0.50) LMNAGAAKMT2AALDH1A1TSHR
SCHEMBL14428178 0.79 KMT2A (0.50) LMNAGAAKMT2AALDH1A1TSHR
SCHEMBL1134249 0.79 LMNA (0.50) LMNAGAAKMT2AALDH1A1TSHR
SCHEMBL28439990 0.79 TRIM24 (0.61) LMNAGAAKMT2AALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3246317-B1 BTK INHIBITOR HUBEI BIO PHARMACEUTICAL INDUSTRIAL TECH INSTITUTE INC (CN) 2023-02-22 EP disclosed
US-10662174-B2 BTK inhibitor HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2020-05-26 US disclosed
US-10450292-B2 Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols Rutgers, The State University of New Jersesy (US) 2019-10-22 US disclosed
CN-109890821-A Amino-pyrrolopyrimidine ketone compound and its application method 艾科尔公司 2019-06-14 CN disclosed
US-20190023682-A1 INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2019-01-24 US disclosed
EP-3246317-A1 BTK INHIBITOR Hubei Bio-Pharmaceutical Industrial Technological Institute Inc. (CN) 2017-11-22 EP disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 US disclosed
US-20170313683-A1 BTK INHIBITOR HUBEI BIO-PHARMACEUTICAL INDUSTRIAL TECHNOLOGICAL INSTITUTE, INC. (CN) 2017-11-02 US disclosed
WO-2017100645-A2 INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS RUTGERS, THE STATE UNIVERSITY OF NEW JERSEY (US) 2017-06-15 WO disclosed
CN-105278268-A Electrostatic charge image developing toner, electrostatic charge image developer, and toner cartridge FUJI XEROX CO LTD 2016-01-27 CN disclosed
EP-0677039-A1 CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE Abbott Laboratories (US) 1995-10-18 EP disclosed
WO-1995012572-A1 CYCLOBUTANE DERIVATIVES AS INHIBITORS OF SQUALENE SYNTHETASE AND PROTEIN FARNESYLTRANSFERASE ABBOTT LABORATORIES (US) 1995-05-11 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190023682-A1 INHIBITORS OF BACTERIAL RNA POLYMERASE: ARYLPROPANOYL, ARYLPROPENOYL, AND ARYLCYCLOPROPANECARBOXYL PHLOROGLUCINOLS RNGTT, ELL, PGLS LMNA 4180/4885GAA 373/4885KMT2A 917/4885
US-10662174-B2 BTK inhibitor BTK, SYK, LYN LMNA 4722/4885GAA 1783/4885KMT2A 1059/4885
US-20170313683-A1 BTK INHIBITOR BTK, SYK, LYN LMNA 4722/4885GAA 1783/4885KMT2A 1059/4885
US-10450292-B2 Inhibitors of bacterial RNA polymerase: arylpropanoyl, arylpropenoyl, and arylcyclopropanecarboxyl phloroglucinols RNGTT, ELL, PGLS LMNA 4180/4885GAA 373/4885KMT2A 917/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.